{
    "id": "5fdd9cbd-360f-3787-3863-c1172763840f",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "Tasimelteon",
    "organization": "Apotex Corp.",
    "effectiveTime": "20250410",
    "ingredients": [
        {
            "name": "Tasimelteon",
            "code": "SHS4PU80D9"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Fd&C Blue No. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "Fd&C Red No. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "Fd&C Yellow No. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "Shellac",
            "code": "46N107B71O"
        },
        {
            "name": "Sodium Hydroxide",
            "code": "55X04QC32I"
        }
    ],
    "indications": "1 usage tasimelteon capsules melatonin receptor agonist. tasimelteon capsules indicated treatment non ­24-hour sleep-wake disorder ( non-24 ) adults ( 1 ) 1.1 non-24-hour sleep-wake disorder ( non-24 ) tasimelteon capsules indicated treatment non-24 adults.",
    "contraindications": "4 none. none ( 4 )",
    "warningsAndPrecautions": "5 may cause somnolence: taking tasimelteon capsules, patients limit activity preparing going bed, tasimelteon capsules impair performance activities requiring complete mental alertness ( 5.1 ) 5.1 somnolence taking tasimelteon capsules, patients limit activity preparing going bed. tasimelteon capsules potentially impair performance activities requiring complete mental alertness.",
    "adverseReactions": "6 common ( incidence >5% least twice high tasimelteon placebo ) headache, increased alanine aminotransferase, nightmares unusual dreams, upper respiratory urinary tract infection ( 6.1 ) report suspected reactions, contact apotex corp. 1-800-706-5575 fda 1-800-fda-1088 www.fda.gov/medwatch . 6.1 trials experience trials conducted widely varying conditions, reaction rates observed trials cannot directly compared rates trials another may reflect rates observed practice. 2080 subjects treated least one dose tasimelteon, 380 treated > 26 weeks 170 treated > 1 year. non-24-hour sleep-wake disorder ( non-24 ) 26-week, parallel-arm placebo-controlled study ( study 1 ) evaluated tasimelteon ( n=42 ) compared placebo ( n=42 ) patients non-24. randomized-withdrawal, placebo-controlled study 8 weeks duration ( study 2 ) also evaluated tasimelteon ( n=10 ) , compared placebo ( n=10 ) , patients non-24. placebo-controlled studies, 6% patients exposed tasimelteon discontinued treatment due event, compared 4% patients received placebo. table 2 shows incidence study 1. table 2: study 1 tasimelteon n=42 placebo n=42 headache 17 % 7 % alanine aminotransferase increased 10 % 5 % nightmare/abnormal dreams 10 % 0 % upper respiratory tract infection 7 % 0 % urinary tract infection 7 % 2 % *adverse incidence > 5% least twice high tasimelteon placebo displayed.",
    "indications_original": "1 INDICATIONS AND USAGE Tasimelteon capsules are a melatonin receptor agonist. Tasimelteon capsules are indicated for the treatment of Non ­24-Hour Sleep-Wake Disorder (Non-24) in adults ( 1 ) 1.1 Non-24-Hour Sleep-Wake Disorder (Non-24) Tasimelteon capsules are indicated for the treatment of Non-24 in adults.",
    "contraindications_original": "4 CONTRAINDICATIONS None. None ( 4 )",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS May cause somnolence: After taking tasimelteon capsules, patients should limit their activity to preparing for going to bed, because tasimelteon capsules can impair the performance of activities requiring complete mental alertness ( 5.1 ) 5.1 Somnolence After taking tasimelteon capsules, patients should limit their activity to preparing for going to bed. Tasimelteon capsules can potentially impair the performance of activities requiring complete mental alertness.",
    "adverseReactions_original": "6 ADVERSE REACTIONS The most common adverse reactions (incidence >5% and at least twice as high on tasimelteon than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. More than 2080 subjects have been treated with at least one dose of tasimelteon, of which more than 380 have been treated for > 26 weeks and more than 170 have been treated for > 1 year. Non-24-Hour Sleep-Wake Disorder (Non-24) A 26-week, parallel-arm placebo-controlled study (Study 1) evaluated tasimelteon (n=42) compared to placebo (n=42) in patients with Non-24. A randomized-withdrawal, placebo-controlled study of 8 weeks duration (Study 2) also evaluated tasimelteon (n=10), compared to placebo (n=10), in patients with Non-24. In placebo-controlled studies, 6% of patients exposed to tasimelteon discontinued treatment due to an adverse event, compared with 4% of patients who received placebo. Table 2 shows the incidence of adverse reactions from Study 1. Table 2: Adverse Reactions in Study 1 Tasimelteon N=42 Placebo N=42 Headache 17 % 7 % Alanine aminotransferase increased 10 % 5 % Nightmare/abnormal dreams 10 % 0 % Upper respiratory tract infection 7 % 0 % Urinary tract infection 7 % 2 % *Adverse reactions with an incidence > 5% and at least twice as high on tasimelteon than on placebo are displayed."
}